Further studies are needed to better characterize the relationship between ROS1-GOPC fusion with the pathogenesis of nasopharyngeal papillary adenocarcinoma and response to TKIs such as crizotinib and lorlatinib toward this carcinoma. The gene discussed is ROS1; the disease is carcinoma.